Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
vDd5VqHpk7jDkuwG
Listen
